Unlike the cancer cells treated with trastuzumab and PBMCs, cancer cells treated with the scIgG-T, N297A-T, or F(ab’)2-T in the presence of PBMCs showed no HER2 downregulation (Figure 2A). The gene discussed is ERBB2; the disease is cancer.